RxSight CFO exercises RSUs, withholds shares for taxes

RxSight, Inc. Chief Financial Officer Mark Wilterding reported equity award activity involving restricted stock units and related common stock.

Rhea-AI Filing Summary

RxSight, Inc. Chief Financial Officer Mark Wilterding reported equity award activity involving restricted stock units and related common stock. On February 28, 2026, 20,441 restricted stock units were exercised into 20,441 shares of common stock at a price of $0.00 per share. To cover tax obligations on this vesting event, 8,068 shares of common stock were disposed of at $7.61 per share through a tax-withholding arrangement rather than an open-market sale. Footnotes state that one eighth of the RSU award vested on February 28, 2026, with additional one-eighth installments scheduled to vest every six months through the end of a four-year period, subject to continued service.

Insider Trade Summary

20,441 shares exercised/converted

Exercise 3 txns

Insider Wilterding Mark

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	20,441	$0.00	$0.00
Exercise	Common Stock	20,441	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	8,068	$7.61	$61K

Holdings After Transaction: Restricted Stock Unit — 143,087 contracts (Direct); Common Stock — 12,373 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. F2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award vested on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did RxSight (RXST) report for CFO Mark Wilterding?

RxSight reported that CFO Mark Wilterding exercised 20,441 restricted stock units into 20,441 common shares and disposed of 8,068 shares to satisfy tax obligations. These transactions occurred on February 28, 2026 and were related to equity compensation vesting, not open-market buying or selling.

Did the RxSight (RXST) CFO sell shares on the open market in this Form 4?

No open-market sale was reported. The Form 4 shows 8,068 shares of common stock disposed of under code "F" to pay tax liabilities associated with the RSU vesting. This represents tax withholding using shares rather than a discretionary sale into the public market.

How many RxSight (RXST) shares did the CFO acquire through RSUs in this filing?

The CFO acquired 20,441 shares of RxSight common stock through the exercise of 20,441 restricted stock units at $0.00 per share. Each restricted stock unit represents a contingent right to receive one share of common stock upon vesting under the company’s 2021 Equity Incentive Plan.

What is the vesting schedule for the RxSight (RXST) RSUs reported in this Form 4?

The RSU award vests over four years, subject to continued service. One eighth of the shares vested on February 28, 2026, and one eighth will vest every six months thereafter on the last day of February and the last day of August for the remainder of the period.

How were tax obligations handled for the RxSight (RXST) CFO’s RSU vesting?

Tax obligations were covered through a share disposition coded "F". Specifically, 8,068 common shares were delivered at $7.61 per share to satisfy tax liabilities, rather than paying cash, which is a common mechanism for equity award tax withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilterding Mark

(Last) (First) (Middle)

100 COLUMBIA

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RxSight, Inc. [ RXST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/28/2026		M		20,441	A	(1)	20,441	D
Common Stock	02/28/2026		F		8,068	D	$7.61	12,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/28/2026		M			20,441	(2)	(2)	Common Stock	20,441	$0	143,087	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award vested on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jim Schindler, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.